Case Report: Precision Medicine Target Revealed by In Vitro Modeling of Relapsed, Refractory Acute Lymphoblastic Leukemia From a Child With Neurofibromatosis

Simple item page
dc.contributor.authorHeatley, S.L.
dc.contributor.authorPage, E.C.
dc.contributor.authorEadie, L.N.
dc.contributor.authorMcClure, B.J.
dc.contributor.authorRehn, J.
dc.contributor.authorYeung, D.T.
dc.contributor.authorOsborn, M.
dc.contributor.authorRevesz, T.
dc.contributor.authorKirby, M.
dc.contributor.authorWhite, D.L.
dc.date.issued2022
dc.description.abstractChildren with neurofibromatosis have a higher risk of developing juvenile myelomonocytic leukemia and acute myeloid leukemia, but rarely develop B-cell acute lymphoblastic leukemia (B-ALL). Through in-vitro modeling, a novel NF1 p.L2467 frameshift (fs) mutation identified in a relapsed/refractory Ph-like B-ALL patient with neurofibromatosis demonstrated cytokine independence and increased RAS signaling, indicative of leukemic transformation. Furthermore, these cells were sensitive to the MEK inhibitors trametinib and mirdametinib. Bi-allelic NF1 loss of function may be a contributing factor to relapse and with sensitivity to MEK inhibitors, suggests a novel precision medicine target in the setting of neurofibromatosis patients with B-ALL.
dc.description.statementofresponsibilitySusan L. Heatley, Elyse C. Page, Laura N. Eadie, Barbara J. McClure, Jacqueline Rehn, David T. Yeung, Michael Osborn, Tamas Revesz, Maria Kirby, and Deborah L. White
dc.identifier.citationFrontiers in Oncology, 2022; 12:851572-1-851572-6
dc.identifier.doi10.3389/fonc.2022.851572
dc.identifier.issn2234-943X
dc.identifier.issn2234-943X
dc.identifier.orcidHeatley, S.L. [0000-0001-7497-6477]
dc.identifier.orcidPage, E.C. [0000-0002-8990-2574]
dc.identifier.orcidEadie, L.N. [0000-0003-1912-7602]
dc.identifier.orcidMcClure, B.J. [0000-0002-5201-4127]
dc.identifier.orcidRehn, J. [0000-0001-5043-6943]
dc.identifier.orcidYeung, D.T. [0000-0002-7558-9927]
dc.identifier.orcidOsborn, M. [0000-0002-1288-9930]
dc.identifier.orcidRevesz, T. [0000-0003-2501-0259]
dc.identifier.orcidWhite, D.L. [0000-0003-4844-333X]
dc.identifier.urihttps://hdl.handle.net/2440/135799
dc.language.isoen
dc.publisherFrontiers Media
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/1057746
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/1044884
dc.rightsCopyright © 2022 Heatley, Page, Eadie,McClure, Rehn, Yeung, Osborn, Revesz, Kirby and White. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
dc.source.urihttps://www.frontiersin.org/articles/10.3389/fonc.2022.851572/full
dc.subjectacute lymphoblastic leukemia
dc.subjectrelapsed/refractory ALL
dc.subjectneurofibromatosis
dc.subjectPh-like ALL
dc.subjectiAMP21-ALL
dc.titleCase Report: Precision Medicine Target Revealed by In Vitro Modeling of Relapsed, Refractory Acute Lymphoblastic Leukemia From a Child With Neurofibromatosis
dc.typeJournal article
pubs.publication-statusPublished

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
hdl_135799.pdf
Size:
1.32 MB
Format:
Adobe Portable Document Format
Description:
Published version
Download

Collections

Medicine publications